Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 3/20 | 0.57 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.55 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.55 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.55 |
| ▸ | CES2 | O00748 | 2/20 | 0.54 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
| ▸ | KIF11 | P52732 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.47 |
| ▸ | WNT3A | P56704 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7797579 | 1.00 | KMO (0.57) | KMOSLC1A3SLC1A2SLC1A1CES2 | |
| SCHEMBL7797588 | 1.00 | KMO (0.57) | KMOSLC1A3SLC1A2SLC1A1CES2 | |
| SCHEMBL5122306 | 0.84 | CES2 (0.56) | KMOCES2SRD5A2NPSR1LMNA | |
| SCHEMBL11151625 | 0.82 | NPSR1 (0.55) | CES2SRD5A2NPSR1LMNACTNNB1 | |
| SCHEMBL7800743 | 0.81 | PDPK1 (0.60) | KMOSLC1A3SLC1A2SLC1A1CES2 | |
| SCHEMBL13222715 | 0.80 | NPSR1 (0.59) | CES2SRD5A2NPSR1LMNACTNNB1 | |
| SCHEMBL7797488 | 0.80 | KMO (0.61) | KMOSLC1A1CES2LMNACTNNB1 | |
| SCHEMBL7797494 | 0.80 | KMO (0.61) | KMOSLC1A1CES2LMNACTNNB1 | |
| SCHEMBL7797498 | 0.80 | KMO (0.61) | KMOSLC1A1CES2LMNACTNNB1 | |
| SCHEMBL9585972 | 0.80 | NPSR1 (0.52) | CES2SRD5A2NPSR1LMNACTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010008947-A1 | 2-AMINO-4-PHENYL-4-OXO-BUTYRIC ACID DERIVATIVES | VARASI MARIO (IT) | 2001-07-19 | — | — | US | disclosed |
| EP-0662948-B1 | 2-AMINO-4-PHENYL-4-OXO-BUTYRIC ACID DERIVATIVES WITH KYNURENINASE AND/OR KYNURENINE-3-HYDROXYLASE INHIBITING ACTIVITY | PHARMACIA & UPJOHN SPA (IT) | 1998-10-07 | — | — | EP | disclosed |
| EP-0662948-A1 | 2-AMINO-4-PHENYL-4-OXO-BUTYRIC ACID DERIVATIVES WITH KYNURENINASE AND/OR KYNURENINE-3-HYDROXYLASE INHIBITING ACTIVITY | PHARMACIA & UPJOHN S.p.A. (IT) | 1995-07-19 | — | — | EP | disclosed |
| WO-1995003271-A1 | 2-AMINO-4-PHENYL-4-OXO-BUTYRIC ACID DERIVATIVES WITH KYNURENINASE AND/OR KYNURENINE-3-HYDROXYLASE INHIBITING ACTIVITY | PHARMACIA S.P.A. (IT) | 1995-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010008947-A1 | 2-AMINO-4-PHENYL-4-OXO-BUTYRIC ACID DERIVATIVES | KYNU, KMO, ABAT | KMO 2/4885SLC1A3 58/4885SLC1A2 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.